CD34+ cell dose and CMV viremia after haploidentical hematopoietic stem cell transplantation: a retrospective study

Peirou Yan,Xinan Pan,Qi Hao,Jingbo Wang
DOI: https://doi.org/10.62347/SOPM3064
2024-09-15
Abstract:Background: Patients with hematologic malignancies who undergo Haplo-HSCT (Haploidentical hematopoietic stem cell transplantation) are at a significantly higher risk for CMV (Cytomegalovirus) infection than individuals with normal immune function. This increased susceptibility to CMV is a major contributor to the morbidity and mortality seen in patients following hematopoietic stem cell transplantation. Methods: This study involved a retrospective analysis of 113 patients who underwent allogeneic hematopoietic stem cell transplantation for malignant hematological diseases. Relevant variables were assessed through univariate analysis, and those identified in the previous literature as potential influencers of the occurrence of CMV viremia were also included in the multivariate regression analysis. Results: Among the 113 patients with malignant hematologic diseases undergoing Haplo-HSCT, 56 cases (49.56%) were identified with CMV viremia. Initial univariate analysis highlighted patient age, graft source, and CD34+ cell dose as risk factors for CMV viremia post-transplantation. However, subsequent logistic regression analysis revealed that CD34+ cell dose stood out as an independent protective factor against CMV viremia (OR = 0.797, 95% CI: 0.644-0.987, P = 0.037). Conclusion: Our study reveals that a higher CD34 cell dosage serves as an independent protective factor against the development of CMV viremia after Haplo-HSCT in patients with hematologic malignancies.
What problem does this paper attempt to address?